Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Daniel Steinhaus

Clinical Cardiac Electrophysiology Kansas City, MO Medical Doctor

NPI 1043447592 CMS profile 905234

4330 Wornall Rd, Ste 2000, Kansas City, MO 64111

Open in the dashboard

General payments

$28,272

85 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Daniel Steinhaus of Kansas City, MO is reported in the CMS Open Payments database as having received $28,272 across 85 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 60th percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $8,029 22
2024 General $337 4
2023 General $7,075 36
2022 General $300 4
2021 General $4,528 4
2020 General $4,532 6
2019 General $3,470 9

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Daniel Steinhaus
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Daniel Steinhaus were reported at $8,029. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Daniel Steinhaus Clinical Cardiac Electrophysiology median Middle half National median
2019 $3,470 $2,361 $585–$8,260 $163
2020 $4,532 $993 $247–$4,351 $114
2021 $4,528 $1,185 $326–$4,739 $132
2022 $300 $2,073 $554–$6,789 $149
2023 $7,075 $2,568 $759–$8,159 $160
2024 $337 $2,557 $703–$7,403 $164
2025 $8,029 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $10,840 13 payments
  2. Impulse Dynamics (USA) Inc. $7,164 14 payments
  3. Abbott Laboratories $5,822 27 payments
  4. Medtronic Vascular, Inc. $2,055 7 payments
  5. Medtronic, Inc. $1,315 18 payments
  6. Ebr Systems, Inc. $694 3 payments
  7. Atricure, Inc. $162 1 payment
  8. Biosense Webster, Inc. $134 1 payment
  9. Cordis US Corp. $86 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $11,500 5 payments
  2. Honoraria $5,100 2 payments
  3. Food and Beverage $4,074 53 payments
  4. Consulting Fee $3,831 4 payments
  5. Travel and Lodging $3,767 21 payments
Products named General payments · program years 2019–2025
  1. OPTIMIZER Cardiovascular Device $7,043 12 payments
  2. OPTIMIZER Cardiovascular Device $7,043 12 payments
  3. General Therapies $5,152 3 payments
  4. General - Therapies $2,500 1 payment
  5. AVEIR $2,066 11 payments
  6. EnSite Precision Cardiac Mapping System $2,000 1 payment
  7. ENSITE $784 8 payments
  8. Ensite Cardiac Mapping System $521 2 payments
  9. Viva $226 1 payment
  10. TACTICATH ABLATION CATHETER, SENSOR ENABLED $178 1 payment
  11. Other $1,681 31 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 27 drugs

Part D claims

2,262

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$640,186

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

27.3%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 417 $485,386
Xarelto Rivaroxaban Brand 61 $80,106
Jardiance Empagliflozin Brand 21 $30,718
Dofetilide Generic 87 $14,261
Flecainide Acetate Generic 154 $10,939
Metoprolol Succinate Generic 276 $4,269
Diltiazem 24hr Er (Cd) Diltiazem Hcl Brand 73 $1,973
Carvedilol Generic 143 $1,732
Potassium Chloride Generic 19 $1,207
Atorvastatin Calcium Generic 145 $1,095

The 10 drugs with the highest cost, of 27 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 78 billing codes

Paid by Medicare

$155,083

Medicare's payments for the services billed

Medicare patients

1,524

Average age 78

Services billed

3,543

663 women, 861 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 64%
Ischemic heart disease 61%
Heart failure 58%
Arthritis 49%
Chronic kidney disease 42%
Diabetes 37%
Depression 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

85 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record